StreetInsider.com News Articles

Form 6-K Pharming Group N.V. For: Sep 11

Fri, 11 Sep 2026 14:59:00 -0400

si-local-file:///var/storage/secattach/20260911/27052571.html

FDA approves Pharming's Joenja for children ages 4 to 11 with APDS

Fri, 11 Sep 2026 14:00:16 -0400

The U.S. Food and Drug Administration has approved a supplemental New Drug Application from Pharming Group N.V. (Euronext Amsterdam: PHARM, Nasdaq: PHAR) for 40 mg and 50 mg twice-daily doses of Joenja (leniolisib) to treat children aged 4 to 11 years weighing at least 27 kg with activated phosphoinositide 3-kinase delta syndrome, known as APDS, a rare primary immunodeficiency.

The approval, announced September 11, 2026, expands the existing Joenja indication, which the FDA first granted in March 2023 for adults and pediatric patients 12 years and older. According to the company, the newly approved doses are expected to be available through

FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.

Fri, 11 Sep 2026 14:00:00 -0400

FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) ages 4 to 11 who weigh at least 27kg
Newly approved Joenja doses are expected to be available in October

Leiden, the Netherlands, September 11, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for 40 mg and 50 mg twice-daily dosing of Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor,

FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.

Fri, 11 Sep 2026 14:00:00 -0400

FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) ages 4 to 11 who weigh at least 27kg
Newly approved Joenja doses are expected to be available in October

Pharming Group to participate in September investor conferences

Wed, 09 Sep 2026 02:00:00 -0400

Leiden, the Netherlands, September 9, 2026: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced that its management will participate in the following investor conferences in the month of September:

H.C. Wainwright 28th Annual Global Investment Conference, New York, September 14, 2026
Fabrice Chouraqui, Chief Executive Officer, will present on Monday, September 14 at 09:30 EDT/15:30 CEST. A live webcast and replay of the presentation will be made available in the “Events and presentations” and “Our news” sections of Pharming’s website.
Morgan Stanley 24th Annual Global Healthcare Conference, New York, September 15, 2026

Pharming Group to participate in September investor conferences

Wed, 09 Sep 2026 02:00:00 -0400

H.C. Wainwright 28th Annual Global Investment Conference, New York, September 14, 2026
Fabrice Chouraqui, Chief Executive Officer, will present on Monday, September 14 at 09:30 EDT/15:30 CEST. A live webcast and replay of the presentation will be made available in the “Events and presentations” and “Our news” sections of Pharming’s website.
Morgan Stanley 24th Annual Global Healthcare Conference, New York, September 15, 2026

Form 6-K Pharming Group N.V. For: Aug 13

Thu, 13 Aug 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260813/26915804.html

Form 6-K Pharming Group N.V. For: Aug 13

Thu, 13 Aug 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260813/26915804.html

Form 6-K Pharming Group N.V. For: Aug 13

Thu, 13 Aug 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260813/26915804.html

Pharming Group (PHAR) PT Raised to $38 at Canaccord

Mon, 03 Aug 2026 06:42:05 -0400

Canaccord analyst Whitney Ijem raised the price target on Pharming Group (NASDAQ: PHAR) to $38.00 (from $37.00) while maintaining a Buy rating.

Pharming Group (PHAR) PT Lowered to $39 at Oppenheimer

Thu, 30 Jul 2026 14:15:27 -0400

(Updated - July 30, 2026 2:15 PM EDT)

Oppenheimer analyst Jeff Jones lowered the price target on Pharming Group (NASDAQ: PHAR) to $39.00 (from $40.00) while maintaining a Outperform rating.

The analyst commented: "On Thursday, PHAR reported (press release) 2Q26 revenue of $90.2M, in line with our estimates, but below consensus, $90.5/99.5M, respectively. Ruconest is seeing pressure from oral Ekterly, as expected, with $72.3M in revenue reported vs. OPCO/consensus of $72.5/82M. Management indicated an expectation for Ruconest to return to growth in 2H26, with ~93% of patients retained on the product during 2Q. Ruconest pressure was offset by strong Joenja performance of

Pharming Group (PHAR) PT Lowered to $39 at Oppenheimer

Thu, 30 Jul 2026 14:15:27 -0400

(Updated - July 30, 2026 2:15 PM EDT)

Oppenheimer analyst Jeff Jones lowered the price target on Pharming Group (NASDAQ: PHAR) to $39.00 (from $40.00) while maintaining a Outperform rating.

Pharming Group N.V. (PHAR) Misses Q2 EPS by 6c

Thu, 30 Jul 2026 06:23:14 -0400

Pharming Group N.V. (NASDAQ: PHAR) reported Q2 EPS of $0.00, $0.06 worse than the analyst estimate of $0.06. Revenue for the quarter came in at $90.2 million versus the consensus estimate of $101.28 million.

For earnings history and earnings-related data on Pharming Group N.V. (PHAR) click here.

Form 6-K Pharming Group N.V. For: Jul 30

Thu, 30 Jul 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260730/26837975.html

Form 6-K Pharming Group N.V. For: Jul 30

Thu, 30 Jul 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260730/26837975.html

Form 6-K Pharming Group N.V. For: Jul 30

Thu, 30 Jul 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260730/26837975.html

Form 6-K Pharming Group N.V. For: Jun 04

Thu, 04 Jun 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260604/26601978.html

Form 6-K Pharming Group N.V. For: Jun 04

Thu, 04 Jun 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260604/26601978.html

Form 6-K Pharming Group N.V. For: Jun 04

Thu, 04 Jun 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260604/26601978.html

Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS